sciclone pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : sciclone pharmaceuticals

SCLN 11.15

0.0%

Oct 20 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Skywatcher who wrote ()	3/23/2000 12:02:00 PM
From: AurumRabosa	Read Replies (1) of 1137

SciClone Pharmaceuticals Announces FDA Approval of Orphan Drug Status for Zadaxin Mar 22, 2000 - SciClone Pharmaceuticals (SCLN) announced that the FDA has granted Orphan Drug Status to Zadaxin, SCLN's lead immunotherapy, "for the treatment of hepatocellular carcinoma, the most common and deadliest form of liver cancer worldwide." SCLN reported that Orphan Drug Status provides for US marketing exclusivity for 7 years upon marketing approval, as well as significant tax benefits and exemptions from FDA application fees. biz.yahoo.com (Answers my earlier question. 7 years after FDA approval marketing approval.)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next